Memantinhydrochlorid Neuraxpharm

Memantine Hydrochloride, the active ingredient in Memantinhydrochlorid Neuraxpharm, is a NMDA receptor antagonist presented as an oral formulation for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults. GNH USA supplies Memantinhydrochlorid Neuraxpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantinhydrochlorid acts on the glutamatergic pathway and is used in Alzheimer’s disease management. - Moderate to severe Alzheimer’s disease: improves cognition and daily functioning. - Mild to moderate Alzheimer’s disease (as adjunct to cholinesterase inhibitors): may provide additional benefit. - Dementia associated with Alzheimer’s disease: helps maintain functional abilities.

Common Side Effects: - Dizziness: transient light‑headedness, especially at treatment initiation. - Headache: mild to moderate intensity, often resolves with continued therapy. - Constipation: reduced bowel movements, manageable with diet. - Confusion: occasional disorientation, typically improves over time. - Somnolence: mild sleepiness, may lessen with dose adjustment. - Hypertension: modest increase in blood pressure in some patients. Serious or Rare Side Effects: - Seizures: rare occurrence, requires immediate medical attention. - Hallucinations: visual or auditory disturbances, may need discontinuation. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Cardiac arrhythmias: irregular heart rhythms, monitor in at‑risk individuals.

Precautions should be observed when prescribing Memantinhydrochlorid. - Renal impairment: dose adjustment may be required. - Hepatic impairment: monitor liver function tests. - History of seizures: use with caution and monitor closely. - Concurrent use with other NMDA antagonists: increased risk of CNS effects. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Memantinhydrochlorid may interact with several medications. Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase adverse CNS effects. - Ketamine: combined use can potentiate neuropsychiatric reactions. - Other NMDA antagonists: heightened risk of dizziness and confusion. Moderate Interactions (Monitor Closely): - Anticholinergic agents: may worsen cognitive impairment. - Central nervous system depressants: increased sedation and drowsiness. - Diuretics: may alter plasma concentrations of memantine.